Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

3.44USD
25 May 2018
Change (% chg)

$-0.17 (-4.71%)
Prev Close
$3.61
Open
$3.56
Day's High
$3.65
Day's Low
$3.44
Volume
71,727
Avg. Vol
93,323
52-wk High
$7.24
52-wk Low
$2.86

Select another date:

Thu, May 10 2018

BRIEF-Chromadex Q1 Loss Per Share $0.15

* Q1 SALES ROSE 95 PERCENT TO $6.6 MILLION Source text for Eikon: Further company coverage:

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage:

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

Select another date: